|
| |
Abstract |
|---|
|
|
|---|
Myofibroblasts have been thought to participate in subepithelial fibrosis in asthma, but the mechanism of myofibroblast induction has not been fully understood. In this study we investigated injury-related myofibroblast induction in a coculture
system of guinea-pig epithelial cells and fibroblasts cocultured
in a human amnion chamber. After pseudostratified epithelial
cells were mechanically scraped, migrated flat epithelial cells
differentiated into cuboidal appearances on Day 4 and then
returned to their original shapes on Day 8. During the course
of the epithelial redifferentiation, it was found by Northern
blot analysis, immunohistochemistry for
-smooth muscle actin, and electron microscopic observation that the myofibroblasts were transiently induced on Day 4. The myofibroblast
induction was inhibited by the blocking of transforming growth
factor (TGF)-
1 and thrombospondin (TSP)-1, indicating that
the activation of TGF-
1 by TSP-1 would induce myofibroblasts. This finding was also supported by a transient upregulation of TSP immunoreactivity and TSP-1 messenger RNA
(mRNA) in fibroblasts. Interestingly, epithelial injury reduced
TGF-
1 immunoreactivity in the amnion membrane but did
not affect TGF-
1 mRNA in epithelial cells and fibroblasts, indicating that TGF-
1 supplied from the extracellular matrix
can participate in myofibroblast induction. Concurrently with
myofibroblast induction, procollagen type I and III mRNAs were upregulated in fibroblasts, and obvious collagen deposition was observed ultrastructurally around the myofibroblasts
compared with the fibroblasts. These results indicate that induced myofibroblasts can be functionally more active in producing collagen than are resting fibroblasts. The present study
suggests that epithelial injury stimulates TGF-
1 release from
the extracellular matrix and its activation via TSP-1 production, causing collagen synthesis through myofibroblast induction.
| |
Introduction |
|---|
|
|
|---|
Myofibroblasts were discovered in granulation tissues as hybrid cells of fibroblasts and smooth muscle cells (SMC), and ultrastructurally they have both contractile elements observed in SMC and well-developed rough endoplasmic reticula found in fibroblasts (1). Myofibroblasts have been found in a variety of normal tissues and various pathologic situations, including wound-healing, fibromatosis, and a stromal reaction to epithelial tumors (2, 3). Although myofibroblasts are believed to be morphologic intermediates of fibroblasts and SMC, they are not functionally intermediate. Myofibroblasts have been reported to have higher collagen-synthesis activity, especially of type III and I, than do fibroblasts (2). With regard to the wound-healing process, myofibroblasts have been suggested to be involved in tissue contraction, which is necessary for wound closure, as well as in production of the extracellular matrix. These results indicate that myofibroblasts with a high level of metabolic activity are induced in tissue remodeling, a level that is likely not the same as that found in fibroblasts and SMC.
There have been many reports concerning the interaction of myofibroblasts and wound-healing in a variety of
tissues (1, 5, 6). In lung tissue, myofibroblasts have been
suggested to participate in granulation and fibrogenesis in
pulmonary sarcoidosis and lung fibrosis (7, 8). It has also
been reported that myofibroblasts are involved in subepithelial fibrosis of the airway in asthma (9), and transforming growth factor (TGF)-
1, one of the strong inducers of myofibroblasts, is partly responsible for this fibrosis
(13). In addition, because TGF-
1 is secreted by most
cells in a latent form, some kinds of activators
such as
thrombospondin (TSP)-1, which has recently been proposed to be a major activator under physiologic conditions
(16)
might be implicated in the remodeling as well. From
these observations, we hypothesized that myofibroblasts
play a central role in the subepithelial fibrogenetic remodeling process in the asthmatic airway, and that epithelial
shedding might be an important trigger leading to this process. Therefore, the following wound-healing model of epithelium was designed.
To explicate the intricate puzzle of myofibroblast pathogenesis in the airway-wall remodeling process, we investigated the effects of mechanical injury to airway epithelial cells on myofibroblast induction in an in vitro culture system. We have previously reported that coculture of guinea-pig tracheal epithelial cells and fibroblasts on and beneath an amnion membrane facilitates the differentiation of pseudostratified epithelial cells, almost identical to those of in vivo trachea (17, 18). Since then we have mechanically scraped epithelial cells as a model of epithelial shedding in asthmatic response and examined myofibroblast induction during the redifferentiation process of epithelial cells.
| |
Materials and Methods |
|---|
|
|
|---|
Isolation of Epithelial Cells and Fibroblasts from Guinea Pig Tracheas
The guinea-pig epithelial cells and fibroblasts were prepared as described previously (17, 18). Female Hartley-strained guinea pigs (Japan SLC Inc., Shizuoka, Japan) were used for the following experiments. The animals were killed by exsanguination under anesthesia with an intraperitoneal injection of 50 mg/kg pentobarbital. Their tracheas were immediately removed, and the tracheal epithelial cells were isolated by mild digestion with 1 mg/ml of pronase (Sigma, St. Louis, MO). The cells were collected by flushing the inside of the tracheal lumen with Dulbecco's modified Eagle's medium/Ham's F-12 (DMEM/F12) containing 5% fetal calf serum (FCS) (GIBCO BRL, Grand Island, NY), washed several times with phosphate-buffered saline (PBS), and resuspended in the culture medium.
After isolation of the epithelial cells, the tracheas were minced
to pieces of around 1 to 2 mm3. The minced pieces were vigorously washed in PBS, and the washing procedure was repeated
until the supernatant became clear to remove the remaining epithelial cells. The pieces were then cultured in Eagle's minimum
essential medium (MEM) containing 10% FCS (GIBCO BRL)
on a six-well culture plate (Corning, Inc., Corning, NY) by replacing the medium every 3 d. It was observed that the fibroblasts migrated from each piece and grew to subconfluence in each well during the first 2 wk. The remaining pieces were then removed by
gentle pipetting, and the outgrowing fibroblasts from those pieces
were harvested from the wells using trypsin ethylenediaminetetraacetic acid. The recovered cells were washed with PBS and
then resuspended in MEM-FCS. Non-spindle-shaped cells were
mechanically removed by a Pasteur pipette under a microscope.
In total, the fibroblasts were passaged five to seven times, and for
each experiment they were immunohistochemically stained with
an anti
-smooth muscle actin (
-SMA) monoclonal antibody
(mAb) (Sigma) to assess the contamination of SMC (18).
Three-Dimensional Cell Culture with Human Amnion Membrane and Experimental Wound Model
Epithelial cells and fibroblasts were cultured in the human amnion chamber using a modified method according to previous reports (17, 18). Briefly, a human amnion was peeled away from the chorion of a normal-term placenta obtained immediately after delivery, and immersed in 0.25 M NH4OH. The epithelial layer and debris of each amnion were scraped off, and the membrane was placed within a tissue-holding device with its epithelial side facing upward. The device was composed of two concentric polycarbonate rings, each having an outside diameter of 30 mm and an inside diameter of 14 mm.
The epithelial cells were seeded over the amnion membrane in the upper compartment of the chambers at 1 × 106 cells/chamber. Each chamber was placed in a six-well culture plate containing 5 ml DMEM/F12-FCS and maintained at 37°C in an incubator with 5% CO2 and 95% air. The epithelial cells were maintained by immersion feeding during the first week of culturing, and were then maintained under air-liquid interface feeding for another 2 wk. Fibroblasts were then seeded on plastic sheets (Wako Pure Chemicals Ltd., Osaka, Japan), which were placed on the bottom of the culture plate at a density of 5 × 105 cells/well. After coculturing the epithelial cells with fibroblasts for 10 d, two scrape-line injuries 1 mm in width were made centrally across the epithelial layer using a Pasteur pipette (Figures 1A and 1B). Each injured site was confirmed by phase-contrast micrography. The denuded epithelial cells were washed out with PBS and continuously cultured with fibroblasts for 2, 4, or 8 d.
|
Electron Microscopic Observations
The amnion membranes with the cultured epithelial cells were removed from the tissue-holding devices before and on Days 2, 4, and 8 after injury. On Day 4 after injury, the plastic sheet on which the fibroblasts were cultured was also detached from the bottom of the six-well culture plate. Each membrane and the plastic sheet were washed twice with PBS, fixed in 2% glutaraldehyde in 0.1 M sodium phosphate buffer (pH 7.2), and postfixed in 1% osmium tetroxide for 1 h in sodium phosphate buffer (0.1 M, pH 7.2). They were then dehydrated in a graded series of ethanol (50 to 100%) followed by propylene oxide, and were embedded in Epon 812 (Abbot, North Chicago, IL). Ultrathin sections were cut using an Ultrotome V 2088 (LKB-Produkter AB, Bromma, Sweden), and stained with uranyl acetate and lead citrate. The sections were evaluated with an electron microscope (H-7000; Hitachi Ltd., Tokyo, Japan).
Immunohistochemistry
Before and on Days 2, 4, and 8 after injury, the cultured fibroblasts on the plastic sheets were fixed in 4% paraformaldehyde solution for 10 min at 4°C, washed with distilled water, and dried. Before and on Day 4 after injury, the amnion membranes with
epithelial cells were fixed in 4% paraformaldehyde for 10 min at
4°C, embedded in OCT compound (Miles, Elkhart, IN), and frozen in isopentane cooled by dry ice. The amnion membranes with
intact epithelial cells were also treated as a control at the same
time. The 8-µm sections were prepared on poly-L-lysine-coated
slides for immunohistochemistry. Immunohistochemical staining
was carried out with mAbs using avidin biotinylated enzyme
complex method (Vectastain kit; Vector Laboratories, Burlingame, CA). Specific primary antibodies included anti-
-SMA at
a concentration of 20 µg/ml, anti-TGF-
1 (Chemicon International, Inc., Temecula, CA) at 10 µg/ml, and anti-TSP (Immunotech, Marseille, France) at 10 µg/ml. The specificity of the anti-
TGF-
1 and anti-TSP antibodies was determined by Western blot
analysis with the protein of the guinea-pig platelets, which revealed a single band. As a control, nonimmune mouse immunoglobulin (Ig) G for anti-
-SMA and anti-TGF-
1, and nonimmune rat IgG for anti-TSP, were used. Color development was
performed with 3,3'-diaminobenzidine tetrahydrochloride (DAB)
as a chromogen, and specimens were counterstained with Myer's hematoxylin.
-SMA-immunoreactive fibroblasts were counted
in a blinded fashion and expressed as the number of cells per 105
µm2 of five different experiments. We present these results as the percentage of
-SMA-positive cells in the total fibroblasts.
Labeling of Apoptotic Cells
Before and on Day 8 after injury, the cultured fibroblasts on the plastic sheets from different experiments were fixed in 4% paraformaldehyde solution for 10 min at 4°C, washed with distilled water, and dried. A deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay was performed to identify the cells undergoing apoptosis using the In Situ Apoptosis Detection Kit (ApopTag; Intergen Company, Purchase, NY) according to the manufacturer's protocol.
DNA Probes
We obtained the guinea-pig complementary DNA (cDNA) of an
-SMA fragment from the total RNA of guinea-pig SMC by
reverse transcription polymerase chain reaction (PCR) using a
GeneAmp RNA PCR kit (Perkin-Elmer, Foster City, CA) with a
set of gene-specific primers, as shown in Table 1. Simultaneously,
the guinea-pig cDNAs of TGF-
1, TSP-1, procollagen
1(I), and
procollagen
1(III) fragments were obtained from the total RNA
of guinea-pig fibroblasts, as well as that of integrin
6 fragment
from the total RNA of guinea-pig epithelial cells. Each primer was
designed on the basis of published cDNA sequences (19). The
amplified PCR products were ligated into pCR II-TOPO vector
(Invitrogen, Carlsbad, CA) and transformed into One Shot chemically competent cells (Invitrogen). After isolating plasmid DNAs
from clones containing the inserts, the plasmids were sequenced by
the dideoxynucleotide chain-termination method with an autosequencer (ABI PRISM-310; Perkin-Elmer). The nucleotides from
the guinea-pig cDNAs were highly homologous to the published sequences (19), and were submitted to the Genbank database
(accession numbers AF169349 for
-SMA, AF169347 for TGF-
1,
AF169345 for TSP-1, AF169346 for procollagen
1[I], AF169348
for procollagen
1[III], and AF169344 for integrin
6).
|
RNA Isolation and Northern Blot Analysis
An RNeasy total RNA kit (Qiagen, Hilden, Germany) was used
to extract the total RNA from fibroblasts and epithelial cells from three different experiments. A 4-µg sample of total RNA
from each cell was electrophoresed on a 4% formaldehyde/1%
agarose gel and transferred to a Hybond N+ nylon membrane filter (Amersham, Little Chalfont, Bucks, UK). Hybridization was
performed with [32P]deoxycytidine triphosphate-labeled
-SMA
cDNA, TGF-
1 cDNA, TSP-1 cDNA, procollagen
1(I) cDNA, and
procollagen
1(III) cDNA at 68°C for 60 min in ExpressHyb hybridization solution (Clontech, Palo Alto, CA). The blots were
washed with 2× 0.15 M NaCl/0.015 M sodium citrate (SSC)/
0.05% sodium dodecyl sulfate (SDS) at room temperature for 30 min, followed by 0.1× SSC/0.1% SDS at 50°C for 30 min. The
membrane was exposed to a BAS-SR imaging plate (Fuji Film, Tokyo, Japan), and analyzed by a BAS5000 imaging analyzer (Fuji
Film). The messenger RNA (mRNA) from each epithelial cell
and fibroblast was quantitated by densitometric analysis. Values
were normalized on the basis of hybridized
-actin mRNA, and
are expressed as percentages of the preinjury values.
TGF-
1 Assay in Culture Medium
The TGF-
1 levels were measured for each coculture supernatant from injured epithelial cells and fibroblasts before and on Days 2, 4, and 8 of injury, and simultaneously from intact cocultured cells. The culture medium was exchanged for fresh DMEM/
F12-FCS 24 h before collection. Sample series from each experiment were continuously collected from three different experiments. Those supernatants were centrifuged at 10,000 × g at 4°C
for 10 min, and then the TGF-
1 immunoreactivities in the samples were analyzed by enzyme-linked immunosorbent assay
(TGF-
1 ELISA kit; R&D Systems, Inc., Minneapolis, MN). In
this assay the minimal detection limit for TGF-
1 was 7 pg/ml,
and no significant cross-reactivities with TGF-
2 and TGF-
3 were observed.
A direct bioassay for TGF-
activity was also carried out.
Growth inhibition of the TGF-
-sensitive mink lung cell line
CCL-64 (American Type Culture Collection, Rockville, MD) was
used to quantify the TGF-
concentrations in the supernatants
(25). Serial dilutions of the supernatants were prepared on 96-well microplates (Corning) to a volume of 100 µl. CCL-64 cells
were seeded at 3 × 104 cells/well and cultured for 3 d in 200 µl
RPMI 1640 (Sigma) with 10% FCS. Subsequently, the inhibition
of cell growth was determined by a tetrazorium-based assay. The
supernatants were carefully removed, and 100 µl of a 1% solution of 3,(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Sigma) in the medium with 10% FCS was added to
each well. After a 1-h incubation at 37°C in 5% CO2/air, the medium was removed and the MTT-formazan crystals were dissolved in 100 µl dimethylsulfoxide (Wako). Plates were placed on
a shaker for 5 min, and the absorbance was measured with a microplate reader (Bio-Rad Laboratories Ltd., Richmond, VA) at a
wave length of 540 nm. Samples were tested in triplicate, and the
TGF-
concentrations were determined by the growth inhibition
caused by the sample, compared with a standard curve obtained
by 1,000-16 pg/ml recombinant TGF-
(Biomedical Technologies,
Inc., Stoughton, MA).
Inhibitory Study Against TGF-
1 and TSP-1
In order to elucidate whether TGF-
1 and TSP-1 are involved in
injury-related myofibroblast induction, we examined the transformation of fibroblasts into myofibroblasts using two neutralizing antibodies against TGF-
1 or TSP (Immunotech), or LSKL,
a peptide that blocks the TSP-1-induced activation of TGF-
(26)
in three different epithelial injury models. Each antibody and the
blocking peptide, at final concentrations of 1 mg/ml, 10 mg/ml,
and 80 nM, were simultaneously added to the culture medium to
inflict the mechanical epithelial injury. The culture medium and
the neutralizing antibodies or blocking peptide were replaced after 36 h. As a control, nonimmune mouse IgG for anti-TGF-
1
and nonimmune rat IgG for anti-TSP were used. On Day 4 after
injury, fibroblasts with and without the blocking reagents were
fixed in 4% paraformaldehyde and subjected to the immunohistochemical study for
-SMA.
Aprotinin (Sigma), an inhibitor of plasmin, was also added to
examine the participation of plasmin in TGF-
1-mediated myofibroblast induction in three different experiments at a concentration of 1,000 U/ml. The transformation of fibroblasts into myofibroblasts was estimated as well.
Statistical Analysis
Data are presented as means ± standard error of the mean (SEM). Statistics were obtained using Statview 5.0 (Abacus Concepts, Inc., Cary, NC). The data from the time-course experiments were analyzed by Dunnett's test as a multiple comparison test, and the data between the two groups were evaluated by an unpaired Student's t test. For all comparisons, statistical significance was accepted as P < 0.05.
| |
Results |
|---|
|
|
|---|
Histologic Analysis of Re-epithelialization
Electron microscopic observations revealed that epithelial cells on an amnion membrane cocultured with fibroblasts show pseudostratified columnar epithelium with ciliated cells and goblet cells (Figure 2A), almost identical to that of the in vivo airway as described previously (18), before injury. With a Pasteur pipette, mechanical scrapes were made across the epithelial layer, and epithelial cells alone were removed from an injured site, whereas the amnion membrane remained undamaged (Figures 1A and 1B). At 1 d after injury (Day 2), the epithelium-denuded part of the amnion membrane was thoroughly covered with flat nonciliated cells (Figure 2B). Redifferentiation of epithelial cells proceeded from the proximal to the distal site of the injury. The epithelial cells were entirely changed to a cuboidal shape with ciliated cells on Day 4 after injury (Figure 2C), and returned to a pseudostratified and columnar epithelium with ciliated cells and goblet cells on Day 8 (Figure 2D).
|
Myofibroblast Induction after Epithelial Shedding
After the fifth passage, the purity of fibroblasts was morphologically and immunohistologically determined. Fibroblasts showed a typical peculiar spindle shape and formed
a confluent monolayer with no piling up of cells. No endothelial and epithelial cells were observed. In addition, these
spindle-shaped cells were not stained with mAb to
-SMA
and keratin (data not shown).
To evaluate the existence of myofibroblasts, immunohistochemical study using
-SMA mAb was performed.
The experiment revealed that
-SMA-immunoreactive fibroblasts increased on Day 4 after injury (71.5 ± 2.8% of
total cell count) compared with those before injury (4.5 ± 1.1% of total cell count), and decreased on Day 8 (18.8 ± 1.2% of total cell count) (Figure 3). To determine whether the expression of
-SMA mRNA was correlated with that
of
-SMA protein, a Northern blot analysis was performed.
The size of the guinea-pig
-SMA mRNA (1.7 kb) was
found to be consistent with that of human
-SMA mRNA
(19). Concurrently,
-actin was recognized by the same
guinea-pig
-SMA cDNA, whose size was consistent with that of human
-actin (2.1 kb) (27). The densitometric quantitation of
-SMA mRNA was normalized on the basis of
hybridized
-actin mRNA, and is expressed as a percentage of the preinjury values to be 537± 357, 5,337 ± 1,616, and 677 ± 464% in fibroblasts on Days 2, 4, and 8 after injury, respectively. A very small amount of
-SMA mRNA
was constitutively expressed in guinea-pig fibroblasts before injury; however, its expression was significantly increased on Day 4 after epithelial injury (P < 0.05) and decreased on Day 8 (Figure 4).
|
|
By electron microscopic observation, myofibroblasts were morphologically confirmed. Fibroblasts on Day 4 after epithelial injury had features of myofibroblasts such as bundles of microfilaments with dense bodies running parallel to the long axis of the cell, notched nuclei, and well-developed rough endoplasmic reticula. In the extracellular space, there were collagen fibers with finer fibrillar materials without periodicity (Figure 5).
|
Investigating the termination of the expression of myofibroblasts on Day 8, we evaluated the presence of apoptosis in our wound-healing model. TUNEL staining was performed against fibroblasts before and on Day 8 after epithelial injury. The number of apoptotic cells was increased on Day 8 (39.2 ± 7.2%), compared with that before injury (1.9 ± 0.5%).
TGF-
1 Expression in the Wound-Healing Model
We examined the expression of TGF-
1 in our wound-healing model. Northern blot analysis demonstrated the
TGF-
1 mRNA levels in epithelial cells and fibroblasts
before and on Days 2, 4, and 8 after injury. The size of the
guinea-pig TGF-
1 mRNA (2.5 kb) was found to be consistent with that of human TGF-
1 mRNA (20). The densitometric quantitation of TGF-
1 mRNA was normalized
on the basis of hybridized
-actin mRNA, and is expressed
as a percentage of the preinjury values to be 110 ± 23, 90 ± 1, and 107 ± 9% in fibroblasts; and 117 ± 12, 97 ± 18, and
110 ± 10% in epithelial cells on Days 2, 4, and 8 after injury, respectively. TGF-
1 mRNA was continuously expressed in those cells; however, there was no significant
change after the injury (Figures 6A and 6B).
|
We also examined the immunohistochemical localization of TGF-
1 of the amnion membrane with injured epithelial cells and fibroblasts during the wound-healing process. The amnion membrane was strongly immunoreactive
to TGF-
1, compared with epithelial cells, before the experimental injury. However, on Day 4 after injury, at the same time the myofibroblasts were induced, the immunoreactivity to TGF-
1 in the amnion membrane disappeared, whereas strong immunoreactivity remained in the
control membrane with noninjured epithelial cells (Figure
7). In contrast, TGF-
1-immunoreactive fibroblasts were found to be increased on Day 4 after injury (Figure 8).
|
|
In addition, we measured the levels of immunoreactive
TGF-
1 in the culture medium obtained before and on
Days 2, 4, and 8 after injury to the epithelial cells. All the
samples were activated by acidic pH before measurement
because active TGF-
1 was not detected in any of the
supernatants. Fresh conditioned medium originally contained 408 ± 51 pg/ml of TGF-
1 due to FCS, of which the
subtraction from the measured level revealed the amount
of TGF-
1 newly released from the coculture system
(within 24 h). TGF-
1 release in the culture medium before and on Days 2, 4, and 8 was 579 ± 200, 936 ± 284, 1,188 ± 310, and 968 ± 410 pg/ml in the injured group;
whereas it was 432 ± 137, 600 ± 200, 726 ± 186, and 611 ± 330 pg/ml in the noninjured group. The culture medium
generated increased quantities of TGF-
1, which were maximal by Day 4 after injury; however, there was no statistical significance (Figure 9). With the bioassay for TGF-
activity, the concentrations of biologically active TGF-
in
the supernatants during the wound-healing process were
undetectable when determined by the inhibitory response of CCL-64 cells using an MTT assay.
|
Expression of TSP Protein and mRNA in Fibroblasts
The measurement of TGF-
1 demonstrated increased levels in the supernatants from Day 4 after injury; however,
the increment was not significant. Moreover, the detectable TGF-
1 was entirely in a latent form. These data suggest the contribution of some kind of TGF-
1 activator,
whose expression might be increased during this wound-healing process. TSP-1 is one possible candidate, as has
been recently described (16). To assess TSP production in the fibroblasts during this experiment, an immunohistochemical study using anti-TSP antibody was performed,
which revealed that the levels of TSP-immunoreactive fibroblasts increased on Day 4 after injury (Figure 10). Total mRNA was extracted from the fibroblasts before and
on Days 2, 4, and 8 after injury and was provided for the
Northern blot analysis. The guinea-pig TSP-1 message
(6.0 kb) was found to be identical in size to the published
human TSP-1 mRNA (21). The densitometric quantitation
of TSP-1 mRNA was normalized on the basis of hybridized
-actin mRNA, and is expressed as a percentage of the
preinjury values to be 217 ± 3, 617 ± 147, and 83 ± 15% in
fibroblasts on Days 2, 4, and 8 after injury, respectively.
The expression of TSP-1 mRNA was slightly detectable before and on Day 2 after injury, significantly increased on
Day 4 (P < 0.05), and returned to control values on Day 8 (Figure 11), with this time course correlating with the induction of myofibroblasts.
|
|
Integrin
v
6 Expression in the Wound-Healing Model
We used Northern blot analysis to estimate the integrin
v
6 mRNA levels in epithelial cells and fibroblasts before and on Days 2, 4, and 8 after epithelial injury. In our
injury model, integrin
v
6 mRNA was found to be continuously expressed in epithelial cells and to demonstrate
no significant change after the injury, whereas it was absent in fibroblasts (data not shown).
Collagen Synthesis in Fibroblasts after Injury
We then determined by Northern blot analysis whether the
expression of procollagen
1(I) and procollagen
1(III)
mRNA was correlated with the time course of the expression of
-SMA mRNA after epithelial injury. Total mRNA
was extracted from fibroblasts before and on Days 2, 4, and
8 after injury. The guinea-pig procollagen
1(I) transcript
was estimated to be 5.8 and 4.8 kb, and the guinea-pig procollagen
1(III) RNA to be 4.9 kb, which is consistent
with published mRNA values (22, 23). The densitometric
quantitation of each mRNA was normalized on the basis
of hybridized
-actin mRNA, and the values are expressed
as percentages of each preinjury value. The values of procollagen
1(I) mRNA were 237 ± 43, 897 ± 129, and 90 ± 15% in fibroblasts on Days 2, 4, and 8 after injury, respectively; and of procollagen
1(III) mRNA on Days 2, 4, and 8 were 243 ± 18, 1,360 ± 155, and 147 ± 37%, respectively. The expression of procollagen
1(I) and procollagen
1(III) mRNA was significantly increased on Day 4 after epithelial injury (P < 0.05) and decreased on Day 8 (Figure 12).
|
Inhibitory Study against TGF-
1 and TSP-1
To confirm the participation of TGF-
1 or TSP-1 in the induction of myofibroblasts, we respectively added either neutralizing antibodies against TGF-
1 or TSP, or LSKL, to the
conditioned medium after epithelial injury, and the number of cells immunoreactive for
-SMA was determined on
Day 4.
-SMA-immunoreactive fibroblasts with the blocking reagents significantly decreased (3.2 ± 1.1% of total cell
count with anti-TGF-
1 antibody; 2.8 ± 0.4% of total cell
count with anti-TSP antibody; and 3.8 ± 1.3% of total cell count
with LSKL) compared with those without blocking reagents (73.6 ± 4.7% of total cell count) (P < 0.05) (Figure 13).
Nevertheless, aprotinin had no inhibitory effect on the expression of
-SMA-immunoreactive fibroblasts (68.9 ± 1.2% of total cell count).
|
To determine whether TGF-
1 is involved in the regulation of collagen synthesis and TSP-1 expression, we performed a Northern blot analysis in the presence of the neutralizing antibody to TGF-
1. The densitometric quantitation
of each mRNA was normalized on the basis of hybridized
-actin mRNA, and the values are expressed as percentages
of each preinjury value. In fibroblasts on Days 2, 4, and 8 after injury with anti-TGF-
1 antibody, the respective values
of procollagen
1(I) mRNA were 103 ± 8.8, 110 ± 20.8, and 100 ± 11.5%; those of procollagen
1(III) mRNA were
100 ± 15.3, 107 ± 6.7, and 107 ± 3.3%; and those of TSP-1
mRNA were 103 ± 8.8, 127 ± 14.5, and 120 ± 15.3%. Compared with the injury model without neutralization (Figures 11 and 12), the expression of procollagen
1(I), procollagen
1(III) and TSP-1 mRNA was not upregulated under TGF-
1-blocking conditions (Figure 14).
|
| |
Discussion |
|---|
|
|
|---|
By the present coculturing system for airway epithelial cells and fibroblasts, we demonstrated myofibroblast induction by means of the mechanical injury of airway epithelial cells. The appearance of myofibroblasts was synchronized with the epithelial redifferentiation process and increased collagen synthesis in fibroblasts, suggesting that even mechanical injury to epithelium causes tissue remodeling. This model could provide the basis for demonstrating of the underlying role of epithelial-mesenchymal interactions during the airway remodeling process.
Myofibroblast induction was defined by the expression
of
-SMA using Northern blot analysis and immunohistochemistry. Ultrastructural observation demonstrated the
development of cytoplasmic bundles of actin microfilaments, enlarged endoplasmic reticula, and notched nuclei
in those cells, all of which are the properties of myofibroblasts. The immunoreactivity of
-SMA was absent before
epithelial injury, although its mRNA was faintly observed.
On Day 4 after injury,
-SMA immunoreactivity and its
mRNA were transiently upregulated. This phenotype
change to that of myofibroblasts was triggered by epithelial shedding and redifferentiation, suggesting a cell-cell interaction between epithelial cells and fibroblasts through
humoral factors.
Previous studies have shown that apoptosis mediates the disappearance of myofibroblasts during wound healing (5, 28). TUNEL staining revealed that the number of apoptotic cells was increased on Day 8 compared with Day 1, which also confirmed the presence of an apoptotic mechanism to terminate myofibroblast expression in our wound-healing model.
It is known that various cytokines are implicated in myofibroblast induction, one of which, TGF-
, has been extensively investigated (2, 29). Zhang and colleagues (30)
have recently reported that TGF-
2 levels increased in
culture supernatants after epithelial damage. There are
only a limited number of differences in the effects of different TGF-
isoforms; however, the specific function of
each isoform is not fully understood. Although it was uncertain whether the anti-TGF-
1 antibody used had cross-reactivity to TGF-
2 or TGF-
3, several studies have
demonstrated high basic levels of TGF-
1 expression in
asthmatics (14, 15). Thus, we focused on TGF-
1 in the
present study. We found that neutralization against TGF-
1
significantly suppresses the appearance of myofibroblasts, suggesting that TGF-
1 plays an important role in the induction of myofibroblasts in our model. We further investigated the source and the transition of TGF-
1 by immunohistochemistry and Northern blot analysis. It was found
that the immunoreactivity of TGF-
1 is primarily localized in the amnion membrane and is totally reduced after
epithelial injury, and that mRNA of TGF-
1 in epithelial cells and fibroblasts is not influenced by the injury. Further, TGF-
1 immunoreactivity transiently appeared on
the surface of fibroblasts on Day 4 after injury, which revealed that the cellular localization of TGF-
1-protein expression was increased, whereas no active forms of TGF-
1
were detected in any culture medium. These findings suggest that both newly synthesized TGF-
1 and that stored
in the amnion membrane might be supplied for myofibroblast induction in its latent form, and that its activation
might occur at the cell surface of fibroblasts. In vivo, TGF-
1
is released from a wide variety of cells and is largely stored
in the extracellular matrix in a latent form (29). Latent
TGF-
1 is composed of mature TGF-
, latency-associated
protein (LAP), and latent TGF-
binding protein (LTBP),
which is a component of the extracellular matrix microfibrils and binds the latent TGF-
to the extracellular
matrix. An amnion membrane consists of types IV and V
collagen and laminin, which are known to be structural
components of basement membrane, and interfaces with
an avascular collagenous stroma composed of interstitial
types I and II collagen (17, 31). Therefore, the use of an
amnion membrane such as the basement membrane and extracellular matrix in the present work can mimic physiologic conditions, and the accumulation of TGF-
1 in the
amnion membrane could be similar to that in vivo. The
TGF-
signaling is initiated by the proteolytic cleavage of
LTBP, which causes the release of the latent TGF-
from
the extracellular matrix (29). Proteinase-mediated release
might be susceptible to the action of various proteolytic enzymes. Among these, we have already confirmed that
adding trypsin to the amnion would indeed lead to the loss
of TGF-
immunoreactivity (data not shown). Inasmuch
as bronchial epithelium is known to produce proteinases
such as matrix metalloproteinase (32) and trypsin-like protease (33), it is possible that these proteases might participate in the remodeling process.
Recently, TSP-1 has been reported to be a major activator for latent TGF-
in vivo, and we investigated the effects of epithelial injury on the dynamics of TSP-1 in fibroblasts. Northern blot analysis in the present study showed
that TSP-1 mRNA is already expressed in fibroblasts before epithelial shedding and was found to be upregulated
on Day 4 after injury. TSP-immunoreactive fibroblasts were
also found to be increased, in synchronization with TGF-
1 expression. Therefore, we assessed the effects of TSP-1 on
myofibroblast induction by blocking TSP-1 using a specific
neutralizing antibody and LSKL. LSKL is a sequence of
LAP, and TSP-1 interacts with latent TGF-
1 through the
LSKL peptide (26). To block the TSP-1 activation of latent TGF-
1, LSKL was used at a 1,000-fold molar excess
to the latent TGF-
1 level in the conditioned medium. It was found that anti-TSP neutralizing antibody and the blocking peptide had an inhibitory effect on injury-induced myofibroblast formation. Moreover, TSP-1 upregulation was
suppressed by blocking TGF-
1. Thus, TSP-1 and TGF-
1
were closely related to each other in the sense that TSP-1
would activate TGF-
1 and would also be upregulated by
TGF-
1.
We tested for evidence of latent TGF-
1 activation by
two other mechanisms. Plasmin, a serine proteinase, is
known to be an important activator in the coculture of
bovine endothelial cells and SMC (34). To estimate the
participation of plasmin, we investigated the effects of epithelial shedding on myofibroblast induction in the presence or absence of aprotinin, an inhibitor of plasmin. Myofibroblast induction was not suppressed by aprotinin, which revealed that plasmin did not play a major role in TGF-
1-
mediated myofibroblast induction in our in vitro wound-healing model. Integrin
v
6 has also been reported to be
a candidate for activating latent TGF-
1 (35). However, in
our injury model, integrin
v
6 mRNA was found to be
continuously expressed in epithelial cells and to be absent
in fibroblasts. It seems therefore that the integrin
v
6 in
epithelial cells may not account for the activation of TGF-
1
in our model.
Although both fibroblasts and myofibroblasts have collagen-producing activity, the activity has been reported to
be higher in myofibroblasts than in fibroblasts (2). Thus,
several investigators have described a correlation between
the appearance of myofibroblasts and subepithelial fibrosis in the airways (9). To elucidate the role of induced
myofibroblasts in collagen synthesis in our study, we examined the mRNA levels of procollagen I and III in those
cells. We found that those mRNAs were upregulated on
Day 4 after epithelial injury, which was synchronized with
the dynamics of myofibroblast differentiation. Further, we
also found that ultrastructurally there was much precipitation of collagen fibrils around myofibroblasts when compared with fibroblasts. These findings suggest that induced
myofibroblasts have more potent collagen-producing activity than fibroblasts. In addition, blocking TGF-
1 during the wound-healing process resulted in no upregulation of
procollagen mRNA, which confirmed that TGF-
1 is
strongly involved in collagen synthesis.
Our present finding that mechanical injury induces myofibroblasts may partly explain subepithelial fibrosis in asthma.
It has been reported that eosinophil migration into the airway results in the expression of TGF-
in asthma, whereas
there has been no support for such data in another study
(5). In our study, both epithelial cells and fibroblasts were
observed to have TGF-
1-producing activity. Because
most cells have been reported to have the ability to produce TGF-
, the key process in subepithelial fibrosis may be an activation of TGF-
. We have demonstrated that in
injury-induced myofibroblast formation, TGF-
1 is activated on the cell surface of fibroblasts through TSP-1.
That is, myofibroblast-related fibrogenesis would require
the upregulation of such activators as TSP-1 on fibroblasts
rather than an upregulation of TGF-
1 synthesis.
In addition, we have also demonstrated that myofibroblast induction is synchronized with a disappearance of
TGF-
1 from the amnion membrane. Considering the
present finding that mRNA does not change after epithelial injury, TGF-
1 stored in the extracellular matrix may
be used in the urgent repair of tissue. This hypothesis would
also be supported by the preliminary observation that immunoreactivity to TGF-
1 beneath the basement membrane of the guinea-pig airway appears to disappear after
mechanical injury (data not shown).
In conclusion, we believe that airway myofibroblasts
arise from fibroblasts upon stimulation of TGF-
1 and
TSP-1, which leads to active fibrogenesis, and that the
damaged airway epithelium might play a crucial role in the
genesis of these phenomena (see Figure 15). These results
suggest that myofibroblasts are responsible for the airway
remodeling process through epithelial-mesenchymal interactions. Our wound-healing model could become a new
tool for the study of local airway remodeling.
|
| |
Footnotes |
|---|
Addres correspondence to: Y. Uchida, Dept. of Pulmonary Medicine, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575, Japan. E-mail: yuchida{at}md.tsukuba.ac.jp
(Received in original form December 1, 1999 and in revised form August 7, 2000).
Acknowledgments: The authors are grateful to Ms. Noriko Sugae, Ms. Iku Sudo, and Ms. Kikuko Goda for their technical help.
Abbreviations
cDNA, complementary DNA;
DAB, 3,3'-diaminobenzidine tetrahydrochloride;
FCS, fetal calf serum;
Ig, immunoglobulin;
mAb, monoclonal antibody;
mRNA, messenger RNA;
PBS, phosphate-buffered saline;
PCR, polymerase chain reaction;
-SMA,
-smooth muscle actin;
SMC, smooth-muscle cells;
TGF, transforming growth factor;
TSP, thrombospondin;
TUNEL, deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling.
| |
References |
|---|
|
|
|---|
1. Gabbiani, G., G. B. Ryan, and G. Majno. 1971. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 27: 549-550 [Medline].
2. Schmitt-Gräff, A., A. Desmoulière, and G. Gabbiani. 1994. Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity. Virchows Arch. 425: 3-24 [Medline].
3. Schürch, W., T. A. Seemayer, and G. Gabbiani. 1992. Myofibroblast. In The Histology for Pathologists. S. S. Sternberg, editor. Raven Press, Ltd., New York. 109-144.
4. Oda, D., A. M. Gown, J. S. Vande, Berg, and R. Stern. 1990. Instability of the myofibroblast phenotype in culture. Exp. Mol. Pathol. 52: 221-234 [Medline].
5.
Darbey, I.,
O. Skalli, and
G. Gabbiani.
1990.
-Smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing.
Lab. Invest.
63:
21-29
[Medline].
6. Jester, J. V., M. M. Rodrigues, and I. M. Herman. 1987. Characterization of avascular corneal wound healing fibroblasts. Am. J. Pathol. 127: 140-148 [Abstract].
7. Judd, P. A., P. Finnegan, and R. C. Curran. 1975. Pulmonary sarcoidosis: a clinico-pathological study. J. Pathol. 115: 191-198 [Medline].
8. Kuhn, C., and J. A. McDonald. 1991. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Am. J. Pathol. 138: 1257-1265 [Abstract].
9. Roche, W. R., R. Beasley, J. H. Williams, and S. T. Holgate. 1989. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1: 520-524 [Medline].
10. Brewster, C. E. P., P. H. Howarth, R. Djukanovic, J. Wilson, and S. T. Holgate. 1990. Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am. J. Respir. Cell Mol. Biol. 3: 507-511 .
11. Gizycki, M. J., E. Ädelroth, A. V. Rogers, P. M. O'Byrne, and P. K. Jeffery. 1997. Myofibroblast involvement in the allergen-induced late response in mild atopic asthma. Am. J. Respir. Cell Mol. Biol. 16: 664-673 [Abstract].
12. Sun, G., M. A. Stacey, A. Bellini, M. Marini, and S. Mattoli. 1997. Endothelin-1 induces bronchial myofibroblast differentiation. Peptides 18: 1449-1451 [Medline].
13.
Vignola, A. M.,
P. Chanez,
G. Chiappara,
A. Merendino,
E. Pace,
A. Rizzo,
A. M. La Rocca,
V. Bellia,
G. Bonsignore, and
J. Bousquet.
1997.
Transforming growth factor-
expression in mucosal biopsies in asthma and
chronic bronchitis.
Am. J. Respir. Crit. Care Med.
156:
591-599
14.
Ohno, I.,
Y. Nitta,
K. Yamauchi,
H. Hoshi,
M. Honma,
K. Woolley,
P. O'Byrne,
G. Tamura,
M. Jordana, and
K. Shirato.
1996.
Transforming growth
factor
1 (TGF
1) gene expression by eosinophils in asthmatic airway inflammation.
Am. J. Respir. Cell Mol. Biol.
15:
404-409
[Abstract].
15.
Redington, A. E.,
J. Madden,
A. J. Frew,
R. Djukanovic,
W. R. Roche,
S. T. Holgate, and
P. H. Howarth.
1997.
Transforming growth factor-
1 in
asthma: measurement in bronchoalveolar lavage fluid.
Am. J. Respir. Crit.
Care Med.
156:
642-647
16.
Crawford, S. E.,
V. Stellmach,
J. E. Murphy-Ullrich,
S. M. F. Ribeiro,
J. Lawler,
R. O. Hynes,
G. P. Boivin, and
N. Bouck.
1998.
Thrombospondin-1
is a major activator of TGF-
1 in vivo.
Cell
93:
1159-1170
[Medline].
17. Noguchi, Y., Y. Uchida, T. Endo, H. Ninomiya, A. Nomura, T. Sakamoto, Y. Goto, S. Haraoka, T. Shimokama, T. Watanabe, and S. Hasegawa. 1995. The induction of cell differentiation and polarity of tracheal epithelium cultured on the amniotic membrane. Biochem. Biophys. Res. Commun. 210: 302-309 [Medline].
18.
Goto, Y.,
Y. Noguchi,
A. Nomura,
T. Sakamoto,
Y. Ishii,
S. Bitoh,
C. Picton,
Y. Fujita,
T. Watanabe,
S. Hasegawa, and
Y. Uchida.
1999.
In vitro reconstitution of the tracheal epithelium.
Am. J. Respir. Cell Mol. Biol.
20:
312-318
19.
Kamada, S., and
T. Kakunaga.
1989.
The nucleotide sequence of a human
smooth muscle alpha-actin (aortic type) cDNA.
Nucleic Acids Res.
17:
1767
20.
Derynck, R.,
J. A. Jarrett,
E. Y. Chen,
D. H. Eaton,
J. R. Bell,
R. K. Assoian,
A. B. Roberts,
M. B. Sporn, and
D. V. Goeddel.
1985.
Human transforming growth factor-
complementary DNA sequence and expression in
normal and transformed cells.
Nature
316:
701-705
[Medline].
21.
Hennessy, S. W.,
B. A. Frazier,
D. D. Kim,
T. L. Deckwerth,
D. M. Baumgartel,
P. Rotwein, and
W. A. Frazier.
1989.
Complete thrombospondin
mRNA sequence includes potential regulatory sites in the 3' untranslated
region.
J. Cell Biol.
108:
729-736
22.
Li, S.,
J. Khillan, and
D. J. Prockop.
1994.
The complete cDNA coding sequence for the mouse pro
1 (I) chain of type I procollagen.
Matrix Biol.
14:
593-595
.
23.
Ala-Kokko, L.,
S. Kontusaari,
C. T. Baldwin,
H. Kuivaniemi, and
D. J. Prockop.
1989.
Structure of cDNA clones coding for the entire prepro
1 (III) chain
of human type III procollagen: differences in protein structure from type I
procollagen and conservation of codon preferences.
Biochem. J.
260:
509-516
[Medline].
24.
Sheppard, D.,
C. Rozzo,
L. Starr,
V. Quaranta,
D. J. Erle, and
R. Pytela.
1990.
Complete amino acid sequence of a novel integrin
subunit (
6)
identified in epithelial cells using the polymerase chain reaction.
J. Biol.
Chem.
265:
11502-11507
25.
Garrigue-Antar, L.,
I. Barbieux,
B. Lieubeau,
O. Boisteau, and
M. Grégoire.
1995.
Optimisation of CCL64-based bioassay for TGF-
.
J. Immunol. Methods
186:
267-274
[Medline].
26.
Ribeiro, S. M. F.,
M. Poczatek,
S. Schultz-Cherry,
M. Villain, and
J. E. Murphy-Ullrich.
1999.
The activation sequence of thrombospondin-1 interacts
with the latency-associated peptide to regulate activation of latent transforming growth factor-
.
J. Biol. Chem.
274:
13586-13593
27. Ponte, P., S. Ng, J. Engel, P. Gunning, and L. Kedes. 1984. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res. 12: 1687-1696